Alexis Ann LeVee MD; 2025 SABCS: Pre-Operative Gut Microbiome Predicts Complete Response to Immune Checkpoint Inhibition in Patients with Early-stage HER2-positive Breast Cancer

episode

Audio Journal of Oncology Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

NPR News: 09-24-2026 9AM EDT 5 min · 24 Sep 2026 · NPR News Now

9AM ET 09/24/2026 Newscast 3 min · 24 Sep 2026 · Fox News Hourly Update

The Critic Who Finally Came Around | Jeanine Pt. 5 6 min · 24 Sep 2026 · The Best 5 Minute Wine Podcast

Ambitious But Lazy? Use This CIA Trick to Beat 99% of People 19 min · 24 Sep 2026 · EverydaySpy Podcast

Postpartum Fitness & My Boob Job… 1h 15m · 24 Sep 2026 · Pursuit of Wellness

326. Rethinks: The Secrets to Getting the Information You Need from AI 28 min · 24 Sep 2026 · Think Fast Talk Smart: Communication Techniques

Report any issue

Source

Recorded22 Jan 2026

Publisheraudiomedica.com ↗

Handlerec:19315688

Show notes

Alexis Ann LeVee MD presented novel research at the 2025 San Antonio Breast Cancer Symposium. Her team's study, the randomized phase II neoHIP trial, revealed that pre-operative gut microbiome composition predicts pathologic complete response to immune checkpoint inhibition in patients with early-stage HER2-positive breast cancer. This highlights the microbiome's crucial role in influencing treatment outcomes for HER2-positive breast cancer.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in